株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

非アルコール性脂肪性肝炎(NASH)治療薬市場 - サイズ、シェア、見通し、市場機会の分析 2018年〜2026年

Nonalcoholic Steatohepatitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

発行 Coherent Market Insights 商品コード 754971
出版日 ページ情報 英文 187 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.17円で換算しております。
Back to Top
非アルコール性脂肪性肝炎(NASH)治療薬市場 - サイズ、シェア、見通し、市場機会の分析 2018年〜2026年 Nonalcoholic Steatohepatitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
出版日: 2018年11月22日 ページ情報: 英文 187 Pages
概要

非アルコール性脂肪性肝炎(NASH)は、異常脂質血症、肥満、耐糖能異常(IGT)などの危険因子を1つ以上有する患者に頻繁に発症し肝機能障害を引き起こします。非アルコール性脂肪性肝炎(NASH)の病因は明らかになっていませんが、インスリン抵抗性に関連があるとされています。当疾患は、血液検査、画像検査、肝生検により診断されます。

当レポートでは、世界の非アルコール性脂肪性肝炎(NASH)治療薬市場を調査し、市場の概要、治療薬・流通経路・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、市場機会、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場概要

  • レポート概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:治療薬別
    • 市場スニペット:流通経路別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティーマップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な開発
  • パイプライン製品の分析
  • 疫学研究
  • ファイブフォース分析

第4章 非アルコール性脂肪性肝炎(NASH)治療薬市場:治療薬別

  • イントロダクション
  • セニクリビロック(Cenicriviroc)
  • エラフィブラノール(Elafibranor)
  • オカリバ(オベチコール酸)
  • Selonsertib

第5章 非アルコール性脂肪性肝炎(NASH)治療薬市場:流通経路別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第6章 非アルコール性脂肪性肝炎(NASH)治療薬市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • アフリカ
  • 中東

第7章 競合情勢

  • ヒートマップ解析
  • 企業プロファイル
    • AstraZeneca Plc.
    • Conatus Pharmaceuticals
    • Enzo Biochem, Inc.
    • GENFIT SA,
    • Galmed Pharmaceuticals Ltd.
    • Gilead Science
    • Immuron Ltd.
    • Intercepts Pharmaceuticals
    • Novo Nordisk
    • Raptor Pharmaceutical Corporation
    • Tobira Therapeutics, Inc.
  • アナリストの見解

第8章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Nonalcoholic steatohepatitis treatment (NASH) is a syndrome which causes liver damage in non-alcoholic patients. It develops most often in patients with at least one factors such as dyslipidemia, obesity, and glucose intolerance. NASH pathogenesis is not clearly understood however is considered to be linked with insulin resistance. It is diagnosed with the help of blood tests, imaging tests, and sometimes liver biopsy. Treatment of the NASH includes elimination of causes and risk factors such as reducing fat level in the body. NASH is also considered to be one of the chief causes of cirrhosis which can lead to complete liver failure.

Market Dynamics

Obesity, high blood pressure and cholesterol level, type 2 diabetes and metabolic syndrome are the major cause of the NASH onset. Increasing prevalence of these conditions worldwide is expected to drive the global nonalcoholic steatohepatitis treatment market growth during the forecast period. According to the International Diabetes Federation 2017 data, approximately 425 million people were suffering from diabetes in the world and 82 million cases were in the South East Asia region which is expected to reach 151 million by 2045.

However, diagnosis of the NASH can be difficult to catch in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.

Key features of the study:

  • This report provides in-depth analysis of the nonalcoholic steatohepatitis treatment market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global nonalcoholic steatohepatitis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global nonalcoholic steatohepatitis treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for nonalcoholic steatohepatitis treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:
    • Cenicriviroc
    • Elafibranor
    • Ocaliva (Obeticholic Acid)
    • Selonsertib
  • Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Nonalcoholic Steatohepatitis Treatment Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug:
    • Cenicriviroc
    • Elafibranor
    • Ocaliva (Obeticholic Acid)
    • Selonsertib
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug:
    • Cenicriviroc
    • Elafibranor
    • Ocaliva (Obeticholic Acid)
    • Selonsertib
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug:
    • Cenicriviroc
    • Elafibranor
    • Ocaliva (Obeticholic Acid)
    • Selonsertib
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug:
    • Cenicriviroc
    • Elafibranor
    • Ocaliva (Obeticholic Acid)
    • Selonsertib
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug:
    • Cenicriviroc
    • Elafibranor
    • Ocaliva (Obeticholic Acid)
    • Selonsertib
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug:
    • Cenicriviroc
    • Elafibranor
    • Ocaliva (Obeticholic Acid)
    • Selonsertib
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Company Profiles
    • AstraZeneca Plc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Conatus Pharmaceuticals
    • Enzo Biochem, Inc.
    • GENFIT SA
    • Galmed Pharmaceuticals Ltd.
    • Gilead Science
    • Immuron Ltd.
    • Intercepts Pharmaceuticals
    • Novo Nordisk
    • Raptor Pharmaceutical Corporation
    • Tobira Therapeutics, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Research Studies
  • Pipeline Product Analysis
  • Epidemiology Study
  • PORTER'S Five Forces

4. Global Nonalcoholic Steatohepatitis Treatment Market, By Drug, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Cenicriviroc
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Elafibranor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Ocaliva (Obeticholic acid)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Selonsertib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Retail Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Online Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Nonalcoholic Steatohepatitis Treatment Market, By Region, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2016 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Northern Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • AstraZeneca Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Conatus Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Enzo Biochem, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GENFIT SA,
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Galmed Pharmaceuticals Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Gilead Science
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Immuron Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Intercepts Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novo Nordisk
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Raptor Pharmaceutical Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Tobira Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top